Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-MART-1 F5 T Cells in High Risk Melanoma
NCT00706992Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2008
- Primary completion
- Nov 2012
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes in melanoma, sponsored by National Cancer Institute. Started Jun 2008; status: terminated.
02
Drugs
autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00706992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00706992.